Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 6Burkitt Lymphoma 5Leukemia, Biphenotypic, Acute 3Prostatic Neoplasms 2Myelodysplastic Syndromes 2Anemia, Refractory, with Excess of Blasts 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Down Syndrome 1Anemia, Refractory 1

Interventions

pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2blinatumomab 2azathiopurine 2auricularum 2Vincristine 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Mercaptopurine 2Dexamethasone 2Cytarabine 2Calcium Dobesilate 2Asparaginase 2prednylidene 1hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Thioguanine 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Down Syndrome × Hydrocortisone × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡